SynthesisEuropean psychiatry : the journal of the Association of European Psychiatrists2021
EPA guidance on assessment of negative symptoms in schizophrenia.
Synthesis in European psychiatry : the journal of the Association of European Psychiatrists, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 142 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metacognitive Training for Negative Symptoms (MCT Minus)
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
Who cites it
142 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Serotonin type 3 receptor (5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Pooled it
- The association between attachment insecurity and negative symptoms in clinical and non-clinical populations: A systematic review and meta-analysis.Psychology and psychotherapy · 2026Pooled it
- Dance/movement therapy in psychotic disorders and eating disorders: a systematic review.Frontiers in psychiatry · 2026Pooled it
- Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.Clinical drug investigation · 2025Pooled it
- Clinician-Reported Negative Symptom Scales: A Systematic Review of Measurement Properties.Schizophrenia bulletin · 2024Pooled it
- Clinical Assessment Interview for Negative Symptoms (CAINS): A Systematic Review of Measurement Properties.Schizophrenia bulletin · 2024Pooled it
- Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses.The British journal of psychiatry : the journal of mental science · 2023Pooled it
- Disentangling the Relationships Between the Clinical Symptoms of Schizophrenia Spectrum Disorders and Theory of Mind: A Meta-analysis.Schizophrenia bulletin · 2023Pooled it
- European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review.Frontiers in psychiatry · 2022Pooled it
- Treatment effect modifiers of virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: an exploratory moderator analysis of clinical and demographic characteristics in the FaceYourFears trial.Psychological medicine · 2026Trial
- Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).European psychiatry : the journal of the Association of European Psychiatrists · 2026Trial
- Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.CNS neuroscience & therapeutics · 2023Trial
- Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2022Trial
- Article
- Disentangling Anhedonia and Self-Stigma in Schizophrenia Using Bayesian Network Analysis.Alpha psychiatry · 2026Article
- Negative symptoms in schizophrenia: clinical framework linking emotional experience and identity.BJPsych bulletin · 2026Article
- Cost-effectiveness of early intervention in psychosis in Latin America: economic evaluation of Chilean services.BJPsych open · 2026Article
- Deficits in Emotional Face Processing Indexed by N170 Modulation in Chronic and in First Hospitalized Schizophrenia.Clinical EEG and neuroscience · 2026Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the last decades, a renewed interest for negative symptoms (NS) was brought about by the increased awareness that they interfere severely with real-life functioning, particularly when they are primary and persistent.
methodsIn this guidance paper, we provide a systematic review of the evidence and elaborate several recommendations for the conceptualization and assessment of NS in clinical trials and practice.
resultsExpert consensus and systematic reviews have provided guidance for the optimal assessment of primary and persistent negative symptoms; second-generation rating scales, which provide a better assessment of the experiential domains, are available; however, NS are still poorly assessed both in research and clinical settings.This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms. We also encourage clinicians to use second-generation scales, at least to complement first-generation ones.The EPA guidance further recommends the evidence-based exclusion of several items included in first-generation scales from any NS summary or factor score to improve NS measurement in research and clinical settings. Self-rated instruments are suggested to further complement observer-rated scales in NS assessment.Several recommendations are provided for the identification of secondary negative symptoms in clinical settings.
conclusionsThe dissemination of this guidance paper may promote the development of national guidelines on negative symptom assessment and ultimately improve the care of people with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.